From virtual microscopy to systems pathology

2009 ◽  
Vol 455 (2) ◽  
pp. 193-196 ◽  
Author(s):  
Niels Grabe ◽  
Peter Schirmacher
2007 ◽  
Vol 45 (05) ◽  
Author(s):  
F Sipos ◽  
S Spisák ◽  
T Krenács ◽  
O Galamb ◽  
B Galamb ◽  
...  

Author(s):  
Fernanda Somera dos Santos ◽  
Mariana Kiomy Osako ◽  
Gleici da Silva Castro Perdoná ◽  
Márcia Gaião Alves ◽  
Katiuchia Uzzun Sales

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Renata Zelic ◽  
Francesca Giunchi ◽  
Luca Lianas ◽  
Cecilia Mascia ◽  
Gianluigi Zanetti ◽  
...  

AbstractVirtual microscopy (VM) holds promise to reduce subjectivity as well as intra- and inter-observer variability for the histopathological evaluation of prostate cancer. We evaluated (i) the repeatability (intra-observer agreement) and reproducibility (inter-observer agreement) of the 2014 Gleason grading system and other selected features using standard light microscopy (LM) and an internally developed VM system, and (ii) the interchangeability of LM and VM. Two uro-pathologists reviewed 413 cores from 60 Swedish men diagnosed with non-metastatic prostate cancer 1998–2014. Reviewer 1 performed two reviews using both LM and VM. Reviewer 2 performed one review using both methods. The intra- and inter-observer agreement within and between LM and VM were assessed using Cohen’s kappa and Bland and Altman’s limits of agreement. We found good repeatability and reproducibility for both LM and VM, as well as interchangeability between LM and VM, for primary and secondary Gleason pattern, Gleason Grade Groups, poorly formed glands, cribriform pattern and comedonecrosis but not for the percentage of Gleason pattern 4. Our findings confirm the non-inferiority of VM compared to LM. The repeatability and reproducibility of percentage of Gleason pattern 4 was poor regardless of method used warranting further investigation and improvement before it is used in clinical practice.


2010 ◽  
Vol 5 (S1) ◽  
Author(s):  
Gian Kayser ◽  
Ekkehard Vollmer ◽  
Thorsten Wiech ◽  
Sven Seiwerth ◽  
Klaus Kayser

2010 ◽  
Vol 41 (12) ◽  
pp. 1770-1776 ◽  
Author(s):  
Patricia Switten Nielsen ◽  
Jan Lindebjerg ◽  
Jan Rasmussen ◽  
Henrik Starklint ◽  
Marianne Waldstrøm ◽  
...  

2010 ◽  
Vol 49 (02) ◽  
pp. 173-185 ◽  
Author(s):  
H. Tanaka

Summary Objectives: Recent important advances in the human genomics and post-genomic “omics” are now bringing about a new medical care which we call “omics-based medicine”. In this article, we investigated the development and future possibilities of omics-based medicine. Methods: We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities. Results: The first generation of omics-based medicine started with “genomic medicine” based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis. Conclusion: Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.


Sign in / Sign up

Export Citation Format

Share Document